MicroRNA-183 correlates cancer prognosis, regulates cancer proliferation and bufalin sensitivity in epithelial ovarian caner.

Background we intended to explore the functional implication of microRNA-183 (miR-183) in predicting clinical prognosis and regulating cancer proliferation and bufalin sensitivity in epithelial ovarian cancer (EOC). Methods In 75 EOC patients, miR-183 expression was examined, by quantitative RT-PCR (qRT-PCR), between paired EOC tumors and adjacent normal tissues, and between tumor samples from patients at early clinical stages and those at advanced clinical stages. The association of serum miR-183 and patients' clinicopathological variables were examined. The overall survival (OS) was estimated by Kaplan-Meier model. And the possibility of miR-183 as a prognostic biomarker for EOC was examined by cox proportional hazard regression model. In EOC cell lines SKOV3 and ES-2 cells, lentiviral transduction was conducted to genetically suppress miR-183. The effect of miR-183 downregulation on EOC in vitro growth, bufalin sensitivity and in vivo tumorigenicity were examined. Results MiR-183 was highly expressed in EOC tumors, as well ass in patients at advanced clinical stages. Serum miR-183 was significantly associated with major clinicopathological variables in EOC patients, such as clinical stage and lymph node metastases. High level of serum miR-183 was associated with poor OS in EOC patients, and proved to be a potential biomarker for EOC. In EOC cell lines, functional assays demonstrated that miR-183 downregulation inhibited cancer proliferation, enhanced bufalin sensitivity and reduced tumorigenicity in vivo. Conclusion MiR-183 may be a prognostic biomarker for EOC, and inhibiting miR-183 may have therapeutic effect to inhibit tumor growth in EOC.

[1]  J. Kwon Improving survival after endometrial cancer: the big picture , 2015, Journal of gynecologic oncology.

[2]  H. Gabra,et al.  The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future. , 2014, British medical bulletin.

[3]  Zu-jing Yang,et al.  MicroRNA-150 Predicts a Favorable Prognosis in Patients with Epithelial Ovarian Cancer, and Inhibits Cell Invasion and Metastasis by Suppressing Transcriptional Repressor ZEB1 , 2014, PloS one.

[4]  Xinru Wang,et al.  MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression. , 2014, Cellular signalling.

[5]  Li Zhou,et al.  MicroRNA‐23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt‐related transcription factor‐2 , 2014, FEBS letters.

[6]  Q. Cao,et al.  Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer. , 2014, International journal of clinical and experimental pathology.

[7]  S. Shen,et al.  MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer , 2014, Clinical and Translational Oncology.

[8]  Jin Cao,et al.  miR-335 represents an independent prognostic marker in epithelial ovarian cancer. , 2014, American journal of clinical pathology.

[9]  Annette Lee,et al.  Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes , 2013, British Journal of Cancer.

[10]  E. Amankwah,et al.  Global ovarian cancer health disparities. , 2013, Gynecologic oncology.

[11]  Yuan-li He,et al.  Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer , 2012, Oncology reports.

[12]  Hiroshi Kobayashi,et al.  Molecular genetics and epidemiology of epithelial ovarian cancer (Review). , 2011, Oncology reports.

[13]  D. Armstrong,et al.  Recent progress in the diagnosis and treatment of ovarian cancer , 2011, CA: a cancer journal for clinicians.

[14]  Subbaya Subramanian,et al.  MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. , 2010, Cancer research.

[15]  Xiaofei Zheng,et al.  miR-183 inhibits TGF-β1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells , 2010, BMC Cancer.

[16]  Israel Steinfeld,et al.  Novel Rank-Based Statistical Methods Reveal MicroRNAs with Differential Expression in Multiple Cancer Types , 2009, PloS one.

[17]  T. Liang,et al.  The emerging role of microRNAs in immune cell development and differentiation , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[18]  E. Miska,et al.  How microRNAs control cell division, differentiation and death. , 2005, Current opinion in genetics & development.

[19]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[20]  C. Croce,et al.  MicroRNA signatures in human ovarian cancer. , 2007, Cancer research.